Pharmacokinetics and first-pass effects of ϵ-acetamidocaproic acid after administration of zinc acexamate in rats

References

• Bulbena O, Escolar G, Navarro C, Bravo L, Pfeiffer CJ. (1993). Gastroprotective effect of zinc acexamate against damage induced by nonsteroidal antiinflammatory drugs. A morphological study. Dig Dis Sci 38:730–739.
   PubMed Web of Science ®Google Scholar
• Chiou WL. (1978). Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level–time curve. J Pharmacokinet Biopharm 6:539–546.
   PubMedGoogle Scholar
• Choi YH, Lee MG. (2006). Effects of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D1 and 3A1/2 for the metabolism of metformin. Br J Pharmacol 149:424–430.
   PubMed Web of Science ®Google Scholar
• Choi YH, Kim SG, Lee MG. (2006). Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects. J Pharm Sci 95:2543–2552.
   PubMed Web of Science ®Google Scholar
• Choi YH, Lee YS, Bae SH, Kim TK, Lee BY, Lee MG. (2009). Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats. Biopharm Drug Dispos 30:305–317.
   PubMed Web of Science ®Google Scholar
• Conney AH. (1971). Environmental factors influencing drug metabolism. In: La Du BN, Mandel HG, Way EL, eds. Fundamentals of drug metabolism and drug disposition, Baltimore, MD: Williams & Wilkins Company, p 269.
   Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
   PubMed Web of Science ®Google Scholar
• Escolar G, Bulbena O. (1989). Zinc compounds, a new treatment in peptic ulcer. Drugs Exp Clin Res 15:83–89.
   PubMedGoogle Scholar
• Escolar G, Navarro C, Sendros S, Bulbena O. (1987). Effect of cold-restraint stress and zinc acexamate on gastric mucus production in intact glands. Arch Int Pharmacodyn Ther 290:128–137.
   PubMedGoogle Scholar
• Esplugues JV, Bulbena O, Escolar G, Martí-Bonmatí E, Esplugues J. (1985). Effects of zinc acexamate on gastric mucosal resistance factors. Eur J Pharmacol 109:145–151.
   PubMedGoogle Scholar
• Gibaldi M, Perrier D. (1982). Pharmacokinetics, 2nd ed. New York, NY: Marcel Dekker.
   Google Scholar
• Guilarte Lopez-Manas J, Valenzuela BM, Caballero Plasencia AM, Martin Ruiz JL. (1998). Endoscopic, histologic and morphometric evaluation of the gastric mucosa in patients with osteoarthritis treated with piroxicam and zinc acexamate. Gastroenterol Hepatol 21:212–217.
   PubMedGoogle Scholar
• Hsu FH, Prueksaritanont T, Lee MG, Chiou WL. (1987). The phenomenon and cause of the dose-dependent oral absorption of chlorothiazide in rats: extrapolation to human data based on the body surface area concept. J Pharmacokinet Biopharm 15:369–386.
   PubMedGoogle Scholar
• Lam S. (1990). High performance liquid chromatographic assay of Amicar, epsilon-aminocaproic acid, in plasma and urine after pre-column derivatization with o-phthalaldehyde for fluorescence detection. Biomed Chromatogr 4:175–177.
   PubMedGoogle Scholar
• Lee MG, Chiou WL. (1983). Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623–640.
   PubMedGoogle Scholar
• Lee MG, Chen ML, Huang SM, Chiou WL. (1981). Pharmacokinetics of drugs in blood. I. Unusual distribution of gentamicin. Biopharm Drug Dispos 2:89–97.
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee MG, Kim ND. (1994). Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. J Pharmacokinet Biopharm 22:1–17.
   PubMedGoogle Scholar
• Marcel B, Jochen G, Benita K, Karsten J, Christian DK, Michael S, Alexander PO, Volker S, Uwe K, Carsten JK. (Forthcoming 2009). Zinc deficiency impairs wound healing of colon anastomasis in rats. Int J Colorectal Dis (In press).
   Google Scholar
• Mitruka BM, Rawnsley HM. (1982). Clinical biomedical and hematological reference values in normal experimental animals and normal humans, 2nd ed. New York, NY: Masson Publishing USA Inc.
   Google Scholar
• Murakami T, Nakanishi M, Yoshimori T, Okamura N, Norikura R, Mizojiri K. (2003). Separate assessment of intestinal and hepatic first-pass effects using a rat model with double cannulation of the portal and jugular veins. Drug Metab Pharmacokinet 18:252–260.
   PubMedGoogle Scholar
• Navarro C, Escolar G, Camarasa J, Vernetta C, Bulbena O. (1987). Effect of zinc acexamate and raniditine on chronic gastric lesions in the rat. Methods Find Exp Clin Pharmacol 9:427−432.
   PubMedGoogle Scholar
• Navarro C, Bravo ML, Carulla C, Bulbena O. (1994). Gastrotoxic activity and inhibitory effects on gastric mucosal PGE2 production with different non-steroidal anti-inflammatory drugs: modifications induced by pretreatment with zinc acexamate. Prostaglandins Leukot Essent Fatty Acids 50:305–310.
   PubMedGoogle Scholar
• Olivier G, Philippe M, Alain P, Jean-Christophe B, Philippe C. (1987). Comparison of the anti-inflammatory activity of sodium acexamate and zinc acexamate in healing skin wounds in rabbits. Pharmacology 34:296−300.
   Google Scholar
• Pfeiffer CJ, Bulbena O, Esplugues JV, Escolar G, Navarro C, Esplugues J. (1987). Anti-ulcer and membrane stabilizing actions of zinc acexamate. Arch Int Pharmacodyn Ther 285:148–157.
   PubMedGoogle Scholar
• Thomson JM, Turner L, Poller L. (1973). Inhibition of gastric plasmin activity by epsilon-aminocaproic acid. Ann R Coll Surg Engl 53:340–347.
   PubMed Web of Science ®Google Scholar
• Wu JF, Wang MW, Song LS, Liu ZF. (1996). Absorption, tissue distribution, and excretion of zinc acexamate in rats. Acta Pharmacol Sin 17:375−378.
   Google Scholar
• Yamaguchi M. (Forthcoming 2009). Role of nutritional zinc in the prevention of osteoporosis. Mol Cell Biochem (In press).
   Google Scholar
• Yu CT, Guo YL, Zhang ZJ, Xiang BR, An DK. (2000). Effect of solution pH value on the chelation structure of zinc acexamate by electrospray ionization mass spectrometry. Yao Xue Xue Bao 35:913–915.
   PubMedGoogle Scholar
• Yu SY, Bae SK, Kim EJ, Kim YG, Kim SO, Lee DH, Lim H, Lee MG. (2003). Dose-independent pharmacokinetics of a new reversible proton pump inhibitor, KR-60436, after intravenous and oral administration to rats: gastrointestinal first-pass effect. J Pharm Sci 92:1592–1603.
   PubMedGoogle Scholar